US · INSP · MEDICAL - DEVICES
Inspire Medical Systems, Inc. (INSP) intrinsic value and stock valuation
$55.10as of 2026-11-21 · Mkt cap 1.73B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Inspire Medical Systems, Inc. DCF and intrinsic value
InvestorsCraft values INSP with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from INSP’s statements →
Inspire Medical Systems, Inc. Graham Number
Graham Number: $54.44d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2015–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Integer Holdings Corporation (ITGR) $126.97
- Arcus Biosciences, Inc. (RCUS) $15.62
- Brookdale Senior Living Inc. (BKD) $8.86
- Addus HomeCare Corporation (ADUS) $122.50
- LeMaitre Vascular, Inc. (LMAT) $73.61
- Ardent Health Inc. (ARDT) $15.08
- Artivion, Inc. (AORT) $18.16
- PROCEPT BioRobotics Corporation (PRCT) $24.70
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $912M | $802.8M | $624.8M | $407.9M | $233.4M |
| Operating income | $51M | $36.1M | -$-40.27M | -$-47.59M | -$-39.85M |
| Net income | $145.4M | $53.5M | -$-21.15M | -$-44.88M | -$-42.04M |
| EPSd | $4.89M | $1.75M | -$-721.84K | -$-1.6M | -$-1.54M |
| Operating cash flow | $117M | $130.3M | $24.7M | $11.6M | -$-20.12M |
| Capital expenditure | -$-38.5M | -$-39.12M | -$-23.63M | -$-9.1M | -$-4.67M |
| Free cash flow | $78.5M | $91.1M | $1.02M | $2.47M | -$-24.79M |
| Total assets | $918.5M | $808.4M | $676.8M | $564.9M | $295.1M |
| Total debt | $32.2M | $31.8M | $24.9M | $16.4M | $34.1M |
| Net debt | -$-72.66M | -$-118.36M | -$-160.69M | -$-425.18M | -$-180.37M |
| Total equity | $781.2M | $689.7M | $572.5M | $496M | $229.1M |
| Cash and short-term investments | $308.3M | $445.6M | $460.4M | $451.4M | $214.5M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $912M | $802.8M | $624.8M | $407.9M | $233.4M |
| Cost of revenue | $133.2M | $123M | $96.6M | $66.1M | $33.3M |
| Gross profit | $778.8M | $679.8M | $528.2M | $341.7M | $200.1M |
| Research and development expenses | $103.2M | $114.1M | $116.5M | $68.6M | $37.4M |
| Selling, general and administrative expenses | $624.6M | $529.6M | $452M | $320.7M | $202.6M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $727.8M | $643.7M | $568.5M | $389.3M | $240M |
| Cost and expenses | $861M | $766.7M | $665.1M | $455.5M | $273.2M |
| Interest income | $17.5M | $23.3M | $20.6M | $5.05M | $120K |
| Interest expense | $140K | $20K | $0.00 | $1.68M | $2.13M |
| Depreciation and amortization | $14M | $6.55M | $2.85M | $1.86M | $1.22M |
| Ebitda | $79.8M | $65M | -$-17.06M | -$-40.73M | -$-38.62M |
| Operating income | $51M | $36.1M | -$-40.27M | -$-47.59M | -$-39.85M |
| Total other income/expenses, net | $14.7M | $22.4M | $20.4M | $3.32M | -$-2.12M |
| Income before tax | $65.7M | $58.5M | -$-19.91M | -$-44.27M | -$-41.97M |
| Income tax expense | -$-79.72M | $4.94M | $1.25M | $610K | $70K |
| Net income | $145.4M | $53.5M | -$-21.15M | -$-44.88M | -$-42.04M |
| Weighted average shares outstanding | $29.4M | $29.8M | $29.3M | $28.1M | $27.3M |
| Weighted average diluted shares outstanding | $29.8M | $30.5M | $29.3M | $28.1M | $27.3M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $308.3M | $445.6M | $460.4M | $451.4M | $214.5M |
| Net receivables | $119.7M | $93.1M | $89.9M | $61.2M | $34.2M |
| Inventory | $145.3M | $80.1M | $33.9M | $11.9M | $17.2M |
| Total current assets | $583.7M | $630.8M | $593.7M | $530M | $268.5M |
| Property, plant and equipment, net | $121.4M | $95.2M | $62.7M | $24.1M | $16.4M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $96.3M | $71M | $9.14M | $10.5M | $9.94M |
| Total non-current assets | $334.8M | $177.6M | $83.1M | $34.8M | $26.6M |
| Total assets | $918.5M | $808.4M | $676.8M | $564.9M | $295.1M |
| Accounts payable | $36.6M | $38.7M | $38.8M | $26.9M | $11.7M |
| Short-term debt | $2.16M | $1.75M | $0.00 | $1.34M | $9.5M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $96.1M | $88.5M | $78.1M | $61.2M | $41.3M |
| Long-term debt | $30M | $30M | $24.9M | $15.1M | $24.6M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $30.1M | $30.2M | $26.2M | $7.68M | $24.7M |
| Capital lease obligations | $32.2M | $31.8M | $24.9M | $8.87M | $9.11M |
| Total liabilities | $126.2M | $118.7M | $104.3M | $68.9M | $66M |
| Common stock | $30K | $30K | $30K | $30K | $30K |
| Retained earnings | -$-146.49M | -$-291.91M | -$-345.42M | -$-324.27M | -$-279.39M |
| Accumulated other comprehensive income (loss) | $460K | $540K | $800K | -$-90K | -$-60K |
| Total equity | $781.2M | $689.7M | $572.5M | $496M | $229.1M |
| Total investments | $299.8M | $366.4M | $284M | $20.3M | $9.94M |
| Total debt | $32.2M | $31.8M | $24.9M | $16.4M | $34.1M |
| Net debt | -$-72.66M | -$-118.36M | -$-160.69M | -$-425.18M | -$-180.37M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $145.4M | $53.5M | -$-21.15M | -$-44.88M | -$-42.04M |
| Depreciation and amortization | $14M | $6.55M | $2.85M | $1.86M | $1.22M |
| Stock-based compensation | $130.3M | $116M | $82.5M | $52M | $26.2M |
| Change in working capital | -$-87.38M | -$-37.71M | -$-40.78M | $1.81M | -$-6.86M |
| Accounts receivable | -$-26.23M | -$-2.6M | -$-30.22M | -$-27.02M | -$-9.24M |
| Inventory | -$-65.17M | -$-46.23M | -$-22M | $5.34M | -$-8.75M |
| Accounts payable | -$-3.75M | $600K | $9.3M | $14.4M | $4.78M |
| Net cash provided by operating activities | $117M | $130.3M | $24.7M | $11.6M | -$-20.12M |
| Investments in property, plant and equipment | -$-38.5M | -$-39.12M | -$-23.63M | -$-9.1M | -$-4.67M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | $21.5M | -$-113.12M | -$-294.82M | -$-19.6M | $29.1M |
| Common stock issued | $14.6M | $27.8M | $31.1M | $259.6M | $15M |
| Common stock repurchased | -$-175.02M | -$-75M | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-183.45M | -$-52.39M | $14M | $235.1M | $15M |
| Net change in cash | -$-45.34M | -$-35.39M | -$-256.06M | $227.1M | $24M |
| Cash at end of period | $104.8M | $150.2M | $185.5M | $441.6M | $214.5M |
| Operating cash flow | $117M | $130.3M | $24.7M | $11.6M | -$-20.12M |
| Capital expenditure | -$-38.5M | -$-39.12M | -$-23.63M | -$-9.1M | -$-4.67M |
| Free cash flow | $78.5M | $91.1M | $1.02M | $2.47M | -$-24.79M |
Line items
Line items
Line items
About Inspire Medical Systems, Inc.
Inspire Medical Systems, Inc. operates as a medical technology enterprise, concentrating on the development and commercialization of advanced, minimally intrusive therapies for patients diagnosed with obstructive sleep apnea (OSA) across both domestic U.S. and international markets. A cornerstone of its product portfolio is the Inspire system, an innovative neurostimulation solution that offers a safe and proven effective treatment for individuals experiencing moderate to severe forms of OSA. Additionally, the company is pioneering a novel, closed-loop technology designed to continuously track a patient's breathing patterns and administer mild stimulation to the hypoglossal nerve, thereby maintaining an open airway. Founded in 2007, Inspire Medical Systems maintains its corporate headquarters in Golden Valley, Minnesota.
- CEO
- Timothy Herbert
- Employees
- 1.33K
- Beta
- 0.71
Explore
Frequently asked questions
What is the intrinsic value of Inspire Medical Systems, Inc. (INSP)?
Inspire Medical Systems, Inc. (INSP) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is INSP undervalued?
INSP trades at a price of $55.10 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.